{
  "query": "For NGLY1 deficiency, what are the associated genes, and what existing drugs target proteins in those pathways?",
  "nodes": [
    {
      "id": "HGNC:17646",
      "type": "Gene",
      "label": "NGLY1",
      "properties": {
        "name": "N-glycanase 1",
        "ensembl_id": "ENSG00000151092",
        "uniprot_id": "Q96IV0",
        "function": "Deglycosylates denatured N-linked glycoproteins in cytoplasm, assists proteasome-mediated degradation",
        "pathway": "ER-associated degradation (ERAD)"
      }
    },
    {
      "id": "HGNC:28454",
      "type": "Gene",
      "label": "DERL1",
      "properties": {
        "name": "derlin 1",
        "ensembl_id": "ENSG00000136986",
        "uniprot_id": "Q9BUN8",
        "pathway": "ER-associated degradation (ERAD)",
        "interaction_score": 0.905
      }
    },
    {
      "id": "HGNC:12666",
      "type": "Gene",
      "label": "VCP",
      "properties": {
        "name": "valosin containing protein",
        "ensembl_id": "ENSG00000165280",
        "uniprot_id": "P55072",
        "pathway": "ER-associated degradation (ERAD)",
        "function": "Transitional endoplasmic reticulum ATPase",
        "interaction_score": 0.999
      }
    },
    {
      "id": "HGNC:463",
      "type": "Gene",
      "label": "AMFR",
      "properties": {
        "name": "autocrine motility factor receptor",
        "ensembl_id": "ENSG00000159461",
        "uniprot_id": "Q9UKV5",
        "pathway": "ER-associated degradation (ERAD)",
        "function": "E3 ubiquitin ligase",
        "interaction_score": 0.932
      }
    },
    {
      "id": "MONDO:0800044",
      "type": "Disease",
      "label": "NGLY1 deficiency",
      "properties": {
        "name": "congenital disorder of deglycosylation 1",
        "association_score": 0.789,
        "clinical_features": ["global developmental delay", "hyperkinetic movement disorder", "transient transaminase elevation", "hypoalacrima", "peripheral neuropathy"]
      }
    },
    {
      "id": "WP:WP1785",
      "type": "Pathway",
      "label": "Asparagine N-linked glycosylation",
      "properties": {
        "organism": "Homo sapiens",
        "gene_count": 373
      }
    },
    {
      "id": "INTERVENTION:GS-100",
      "type": "TherapeuticIntervention",
      "label": "GS-100",
      "properties": {
        "description": "AAV9 vector-mediated gene transfer of human NGLY1",
        "modality": "gene therapy",
        "phase": "1/2/3",
        "status": "recruiting",
        "nct_id": "NCT:06199531"
      }
    },
    {
      "id": "INTERVENTION:GlcNAc",
      "type": "TherapeuticIntervention",
      "label": "N-acetylglucosamine (GlcNAc)",
      "properties": {
        "description": "Substrate supplementation therapy for tear production",
        "modality": "small molecule supplement",
        "phase": "2",
        "status": "active_not_recruiting",
        "nct_id": "NCT:05402345"
      }
    },
    {
      "id": "NCT:06199531",
      "type": "ClinicalTrial",
      "label": "GS-100 Gene Therapy Trial",
      "properties": {
        "title": "Phase 1/2/3 Study of GS-100 AAV9 Gene Transfer in NGLY1 Deficiency",
        "status": "RECRUITING",
        "sponsor": "Grace Science, LLC",
        "enrollment_age": "2-18 years",
        "primary_outcome": "Safety, tolerability, and efficacy over 5 years"
      }
    },
    {
      "id": "NCT:05402345",
      "type": "ClinicalTrial",
      "label": "GlcNAc for Tear Production Trial",
      "properties": {
        "title": "Phase II Study of GlcNAc for Tear Production in NGLY1-CDDG",
        "status": "ACTIVE_NOT_RECRUITING",
        "sponsor": "Eva Morava-Kozicz",
        "enrollment_age": "1-60 years",
        "primary_outcome": "Difference in tear production after 6 weeks"
      }
    }
  ],
  "edges": [
    {
      "source": "HGNC:17646",
      "target": "MONDO:0800044",
      "type": "ASSOCIATED_WITH",
      "properties": {
        "score": 0.789,
        "evidence": "Open Targets disease association"
      }
    },
    {
      "source": "HGNC:17646",
      "target": "HGNC:28454",
      "type": "INTERACTS_WITH",
      "properties": {
        "score": 0.905,
        "database": "STRING",
        "evidence_types": ["association", "experiments", "databases", "textmining"]
      }
    },
    {
      "source": "HGNC:17646",
      "target": "HGNC:463",
      "type": "INTERACTS_WITH",
      "properties": {
        "score": 0.932,
        "database": "STRING",
        "evidence_types": ["association", "experiments", "databases", "textmining"]
      }
    },
    {
      "source": "HGNC:28454",
      "target": "HGNC:12666",
      "type": "INTERACTS_WITH",
      "properties": {
        "score": 0.999,
        "database": "STRING",
        "evidence_types": ["experiments", "databases", "textmining"]
      }
    },
    {
      "source": "HGNC:17646",
      "target": "WP:WP1785",
      "type": "MEMBER_OF",
      "properties": {
        "database": "WikiPathways"
      }
    },
    {
      "source": "INTERVENTION:GS-100",
      "target": "HGNC:17646",
      "type": "REPLACES",
      "properties": {
        "mechanism": "gene replacement therapy via AAV9 vector"
      }
    },
    {
      "source": "INTERVENTION:GlcNAc",
      "target": "MONDO:0800044",
      "type": "TREATS_SYMPTOM",
      "properties": {
        "symptom": "hypoalacrima",
        "mechanism": "substrate supplementation"
      }
    },
    {
      "source": "NCT:06199531",
      "target": "INTERVENTION:GS-100",
      "type": "EVALUATES",
      "properties": {
        "phase": "1/2/3"
      }
    },
    {
      "source": "NCT:05402345",
      "target": "INTERVENTION:GlcNAc",
      "type": "EVALUATES",
      "properties": {
        "phase": "2"
      }
    }
  ],
  "metadata": {
    "protocol": "Fuzzy-to-Fact",
    "phases_completed": ["ANCHOR", "ENRICH", "EXPAND", "TRAVERSE_DRUGS", "TRAVERSE_TRIALS", "VALIDATE", "PERSIST"],
    "date_generated": "2026-02-07",
    "validation_status": "all_entities_validated",
    "key_findings": {
      "associated_genes": ["NGLY1", "DERL1", "VCP", "AMFR"],
      "pathway": "ER-associated degradation (ERAD)",
      "approved_drugs": "None (rare disease with no approved therapies)",
      "investigational_therapies": ["GS-100 gene therapy", "N-acetylglucosamine supplementation"],
      "active_trials": 2
    }
  }
}
